Bio Plus Co., Ltd

KOSDAQ:A099430 Stock Report

Market Cap: ₩198.2b

Bio Plus Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Hyun-Kyu Jung

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership29.2%
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

Analysis Article • Jan 30

Is Bio Plus (KOSDAQ:099430) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Nov 27

We Think That There Are More Issues For Bio Plus (KOSDAQ:099430) Than Just Sluggish Earnings

Bio Plus Co., Ltd's ( KOSDAQ:099430 ) recent weak earnings report didn't cause a big stock movement. Our analysis...
Analysis Article • Nov 10

Bio Plus' (KOSDAQ:099430) Dividend Will Be ₩50.00

Bio Plus Co., Ltd ( KOSDAQ:099430 ) will pay a dividend of ₩50.00 on the 13th of April. The dividend yield is 0.8...
Analysis Article • Aug 18

Bio Plus (KOSDAQ:099430) Seems To Use Debt Quite Sensibly

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Jul 22

Capital Allocation Trends At Bio Plus (KOSDAQ:099430) Aren't Ideal

There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...
Analysis Article • May 09

What Bio Plus Co., Ltd's (KOSDAQ:099430) 26% Share Price Gain Is Not Telling You

Bio Plus Co., Ltd ( KOSDAQ:099430 ) shareholders have had their patience rewarded with a 26% share price jump in the...
Analysis Article • Mar 31

Bio Plus' (KOSDAQ:099430) Anemic Earnings Might Be Worse Than You Think

The subdued market reaction suggests that Bio Plus Co., Ltd's ( KOSDAQ:099430 ) recent earnings didn't contain any...
Analysis Article • Feb 14

Does Bio Plus (KOSDAQ:099430) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Jan 07

Bio Plus Co., Ltd's (KOSDAQ:099430) Shares Climb 30% But Its Business Is Yet to Catch Up

Despite an already strong run, Bio Plus Co., Ltd ( KOSDAQ:099430 ) shares have been powering on, with a gain of 30% in...
Analysis Article • Dec 15

Bio Plus (KOSDAQ:099430) Is Reinvesting At Lower Rates Of Return

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Analysis Article • Nov 23

Bio Plus Co., Ltd's (KOSDAQ:099430) Shareholders Might Be Looking For Exit

Bio Plus Co., Ltd's ( KOSDAQ:099430 ) price-to-earnings (or "P/E") ratio of 14.9x might make it look like a sell right...
Analysis Article • Jul 23

Earnings Not Telling The Story For Bio Plus Co., Ltd (KOSDAQ:099430) After Shares Rise 29%

Bio Plus Co., Ltd ( KOSDAQ:099430 ) shares have had a really impressive month, gaining 29% after a shaky period...
Analysis Article • Jul 05

The Returns On Capital At Bio Plus (KOSDAQ:099430) Don't Inspire Confidence

What are the early trends we should look for to identify a stock that could multiply in value over the long term...
Analysis Article • Jun 08

More Unpleasant Surprises Could Be In Store For Bio Plus Co., Ltd's (KOSDAQ:099430) Shares After Tumbling 31%

Bio Plus Co., Ltd ( KOSDAQ:099430 ) shareholders that were waiting for something to happen have been dealt a blow with...
Analysis Article • Mar 26

Additional Considerations Required While Assessing Bio Plus' (KOSDAQ:099430) Strong Earnings

Bio Plus Co., Ltd ( KOSDAQ:099430 ) announced strong profits, but the stock was stagnant. Our analysis suggests that...

CEO

Hyun-Kyu Jung

no data
Tenure

Hyun-Kyu Jung serves as Chief Executive Officer of Bio Plus Co., Ltd.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/14 12:06
End of Day Share Price 2026/09/14 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bio Plus Co., Ltd is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hyung Soo KimHanwha Investment & Securities Co., Ltd.
Junghyun KimKyobo Securities Co., Ltd
Jaehee WonShinhan Investment Corp.